Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 5 studies | 21% ± 5% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 19% ± 4% | |
epithelial cell | 3 studies | 32% ± 7% | |
glutamatergic neuron | 3 studies | 26% ± 10% |
Insufficient scRNA-seq data for expression of CDK9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 7108.38 | 258 / 258 | 100% | 97.25 | 230 / 230 |
esophagus | 100% | 5228.97 | 1445 / 1445 | 100% | 49.94 | 183 / 183 |
liver | 100% | 4151.53 | 226 / 226 | 100% | 49.66 | 406 / 406 |
lung | 100% | 6240.63 | 578 / 578 | 100% | 66.24 | 1155 / 1155 |
ovary | 100% | 10717.30 | 180 / 180 | 100% | 52.01 | 430 / 430 |
pancreas | 100% | 3116.21 | 328 / 328 | 100% | 71.44 | 178 / 178 |
prostate | 100% | 5935.18 | 245 / 245 | 100% | 67.64 | 502 / 502 |
skin | 100% | 4257.39 | 1809 / 1809 | 100% | 59.06 | 472 / 472 |
stomach | 100% | 3861.74 | 359 / 359 | 100% | 49.35 | 286 / 286 |
thymus | 100% | 5870.48 | 653 / 653 | 100% | 92.94 | 605 / 605 |
uterus | 100% | 8562.27 | 170 / 170 | 100% | 76.00 | 459 / 459 |
breast | 100% | 5452.25 | 459 / 459 | 100% | 69.53 | 1117 / 1118 |
brain | 100% | 5193.15 | 2638 / 2642 | 100% | 88.46 | 705 / 705 |
intestine | 100% | 5411.40 | 966 / 966 | 100% | 56.35 | 526 / 527 |
kidney | 100% | 4864.30 | 89 / 89 | 100% | 54.71 | 899 / 901 |
bladder | 100% | 5057.81 | 21 / 21 | 100% | 61.02 | 502 / 504 |
adipose | 100% | 5697.45 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 63.33 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 106.81 | 29 / 29 |
spleen | 100% | 8376.54 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 75.78 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 63.78 | 1 / 1 |
blood vessel | 100% | 4996.65 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 2917.39 | 858 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 3183.55 | 908 / 929 | 0% | 0 | 0 / 0 |
muscle | 96% | 2057.20 | 767 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0120187 | Biological process | positive regulation of protein localization to chromatin |
GO_0006281 | Biological process | DNA repair |
GO_0008283 | Biological process | cell population proliferation |
GO_0140673 | Biological process | transcription elongation-coupled chromatin remodeling |
GO_0051147 | Biological process | regulation of muscle cell differentiation |
GO_0006282 | Biological process | regulation of DNA repair |
GO_0051647 | Biological process | nucleus localization |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0120186 | Biological process | negative regulation of protein localization to chromatin |
GO_0031297 | Biological process | replication fork processing |
GO_0071345 | Biological process | cellular response to cytokine stimulus |
GO_0043923 | Biological process | positive regulation by host of viral transcription |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_0006367 | Biological process | transcription initiation at RNA polymerase II promoter |
GO_0006468 | Biological process | protein phosphorylation |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0031440 | Biological process | regulation of mRNA 3'-end processing |
GO_0008024 | Cellular component | cyclin/CDK positive transcription elongation factor complex |
GO_0008023 | Cellular component | transcription elongation factor complex |
GO_0016020 | Cellular component | membrane |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016605 | Cellular component | PML body |
GO_0070691 | Cellular component | P-TEFb complex |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0003682 | Molecular function | chromatin binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0004672 | Molecular function | protein kinase activity |
GO_0001223 | Molecular function | transcription coactivator binding |
GO_0008353 | Molecular function | RNA polymerase II CTD heptapeptide repeat kinase activity |
GO_0097322 | Molecular function | 7SK snRNA binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003711 | Molecular function | transcription elongation factor activity |
GO_0016301 | Molecular function | kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004693 | Molecular function | cyclin-dependent protein serine/threonine kinase activity |
Gene name | CDK9 |
Protein name | Cyclin-dependent kinase 9 Cyclin dependent kinase 9 Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE) (Tat-associated kinase complex catalytic subunit) |
Synonyms | CDC2L4 TAK |
Description | FUNCTION: Protein kinase involved in the regulation of transcription . Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP . This complex is inactive when in the 7SK snRNP complex form . Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE . Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) . Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis . P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export . Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing . The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro . Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage . In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 . Promotes cardiac myocyte enlargement . RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription . AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect . The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation . Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity . . |
Accessions | X6RE90 P50750 B5BU53 ENST00000421939.5 ENST00000373264.5 [P50750-1] |